Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q12791: Variant p.Gly375Arg

Calcium-activated potassium channel subunit alpha-1
Gene: KCNMA1
Feedback?
Variant information Variant position: help 375 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Arginine (R) at position 375 (G375R, p.Gly375Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LIWAS; loss of voltage-gated potassium channel activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 375 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1236 The length of the canonical sequence.
Location on the sequence: help YGDVYAKTTLGRLFMVFFIL G GLAMFASYVPEIIELIGNRK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Mouse                         YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Rat                           YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Bovine                        YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Rabbit                        YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Chicken                       YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Xenopus laevis                YGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK

Zebrafish                     YGDVYARTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1236 Calcium-activated potassium channel subunit alpha-1
Transmembrane 368 – 388 Helical; Name=Segment S6
Alternative sequence 169 – 1236 Missing. In isoform 6.
Mutagenesis 380 – 380 F -> A. Loss of function.
Mutagenesis 381 – 381 A -> S. Activated at more negative voltages. No effect on inhibition by HMIMP.
Mutagenesis 384 – 384 V -> I. No effect on activation voltage. No effect on inhibition by HMIMP.
Helix 363 – 390



Literature citations
De novo loss-of-function KCNMA1 variants are associated with a new multiple malformation syndrome and a broad spectrum of developmental and neurological phenotypes.
Liang L.; Li X.; Moutton S.; Schrier Vergano S.A.; Cogne B.; Saint-Martin A.; Hurst A.C.E.; Hu Y.; Bodamer O.; Thevenon J.; Hung C.Y.; Isidor B.; Gerard B.; Rega A.; Nambot S.; Lehalle D.; Duffourd Y.; Thauvin-Robinet C.; Faivre L.; Bezieau S.; Dure L.S.; Helbling D.C.; Bick D.; Xu C.; Chen Q.; Mancini G.M.S.; Vitobello A.; Wang Q.K.;
Hum. Mol. Genet. 28:2937-2951(2019)
Cited for: INVOLVEMENT IN LIWAS; VARIANT LIWAS ARG-375; CHARACTERIZATION OF VARIANT LIWAS ARG-375; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.